Keith Greenfield

Keith Greenfield has had a long and varied career in the biotechnology industry. In 1994, they co-founded IQuum, where they served as Director, Executive Vice President of Corporate Development, and investor liaison. In 1999, they founded and became President of The Dover Group, a full service financial planning firm. In 2014, they became Director of AZTherapies, Inc., a biotechnology drug development company. In 2015, they founded NanoTomer, a biotechnology company with a novel approach to targeted cancer treatment. In 2016, they became Director of PhageNova Bio, Inc. and Hoo.be by FNL Technologies. In 2017, they became Director of Xylyx Bio, Inc. In 2019, they founded and became Director of Aloe Attiva and Hessian-Labs. Finally, in 2020, they became Director and Senior Advisor to the CEO at GENERAL FLUIDICS CORPORATION.

Keith Greenfield graduated from the Questrom School of Business at Boston University in 1984 with a Bachelor of Applied Science in Finance.